A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 50 patients (estimated)
- Sponsors
- Dana-Farber Cancer Institute
- Collaborators
- Blood Cancer United
- Tags
- Natural Killer (NK) Cells, Chemotherapy
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 1589
- NCT Identifier
- NCT04024761
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.